Following the closing of its first equity funding in Q4 2023, LimmaTech Biologics has acquired an exclusive clinical development license from AbVacc for LBT-SA7, a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, a bacterial pathogen, affecting approximately 30% of the human population.

LimmaTech Biologics在2023年第四季度结束了第一笔股权融资后，已从AbVacc获得LBT-SA7的独家临床开发许可证，LBT-SA7是一种多价类毒素疫苗候选物，用于预防由金黄色葡萄球菌（一种细菌病原体）引起的感染，影响约30%的人口。

The company will initiate the Phase 1 clinical study in 2024 with an option to acquire full worldwide rights after the trial read-out..

该公司将于2024年启动第一阶段临床研究，并有权在试验宣读后获得全球范围内的全部权利。。

LBT-SA7 is a six-valent toxoid vaccine candidate, designed and developed to date by AbVacc for the prevention of recurrent skin and soft tissue infections (SSTI) caused by Staphylococcus aureus (S. aureus), a Gram-positive bacterial pathogen, causing a spectrum of infections, from skin and soft tissue infections (SSTI) to severe conditions like pneumonia and bloodstream infections.

LBT-SA7是一种六价类毒素候选疫苗，迄今为止由AbVacc设计和开发，用于预防由革兰氏阳性细菌病原体金黄色葡萄球菌（金黄色葡萄球菌）引起的复发性皮肤和软组织感染（SSTI），引起一系列感染，从皮肤和软组织感染（SSTI）到肺炎和血流感染等严重疾病。

S. aureus is the leading cause of antimicrobial resistance (AMR)-attributed fatalities, with community-acquired and hospital-acquired infections being the most prevalent..

S、 金黄色葡萄球菌是导致抗菌素耐药性（AMR）死亡的主要原因，社区获得性和医院获得性感染最为普遍。。

The vaccine candidate contains weakened forms of toxins, referred to as toxoids, that would normally be secreted by the pathogen to cause an infection. The unique formulation of LBT-SA7 enables the body to fight against the infection by eliciting an immune response against the original S. aureus toxins.

候选疫苗含有弱化形式的毒素，称为类毒素，通常由病原体分泌以引起感染。LBT-SA7的独特配方使身体能够通过引发针对原始金黄色葡萄球菌毒素的免疫应答来抵抗感染。

Preclinical studies in mice and rabbits demonstrated strong neutralizing activity against several clinically relevant forms of S. aureus infection. The vaccine candidate also showed efficacy in non-naïve mice pre-exposed to the pathogen..

小鼠和兔子的临床前研究表明，对几种临床相关形式的金黄色葡萄球菌感染具有很强的中和活性。候选疫苗在预先暴露于病原体的非幼稚小鼠中也显示出功效。。

With the in-licencing of LBT-SA7, LimmaTech Biologics has secured the exclusive rights to develop the drug candidate further. LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program. The Zurich-based company is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development.

随着LBT-SA7的获得许可，LimmaTech Biologics获得了进一步开发候选药物的专有权。LimmaTech还获得了一个独家选项，即可执行的第1阶段后读取，以获得该程序的全部权限。这家总部位于苏黎世的公司凭借其在疫苗技术和临床候选药物开发方面无与伦比的记录，在抗击全球抗菌素耐药性流行病方面处于领先地位。

The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections..

该公司正在利用其专有的自我佐剂和多抗原疫苗平台以及其他疾病特异性疫苗方法来预防越来越无法治疗的微生物感染。。

“S. aureus-related infections remain an urgent global medical priority, for which no vaccine is currently available. Based on the original scientific work and the promising preclinical data generated by AbVacc, we aim to rapidly start clinical development and deliver an effective intervention for patients with a broad range of S.

“与金黄色葡萄球菌相关的感染仍然是全球迫切的医学重点，目前尚无疫苗可用。基于原始的科学工作和AbVacc产生的有希望的临床前数据，我们的目标是迅速开始临床开发，并为患有广泛S的患者提供有效的干预措施。

aureus infections,” said Dr Franz-Werner Haas, Chief Executive Officer of LimmaTech. “Building on our extensive vaccine development expertise, including against S. aureus, adding this program to our pipeline is a key milestone in our strategy to pursue innovative approaches to prevent increasingly untreatable microbial infections and positively impact the dangerous rise of antimicrobial resistance.”(Press release/RAN ).

金黄色葡萄球菌感染，”LimmaTech首席执行官Franz Werner Haas博士说。“在我们广泛的疫苗开发专业知识（包括针对金黄色葡萄球菌的疫苗开发专业知识）的基础上，将该计划添加到我们的管道中，是我们追求创新方法以预防越来越无法治疗的微生物感染并对抗菌药物耐药性的危险上升产生积极影响的战略中的一个关键里程碑。”（新闻稿/RAN）。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送